BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

2028

500259

LYKALABS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

LYKA LABS LTD performance

Today’s low

Today’s high

₹ 115.00 ₹ 118.49
₹ 115.53

52 week low

52 week high

₹ 96.80 ₹ 176.59
₹ 115.53

Open Price

₹ 118.49

Prev. Close

₹ 118.75

Volume (Shares)

31882.00

Total traded value

₹ 36.83

Upper Circuit

₹ 142.50

Lower Circuit

₹ 95.00

info

LYKA LABS LTD Share Price Update

As of the latest trading session, LYKA LABS LTD share price is currently at ₹ 115.53, which is down by ₹ -3.22 from its previous closing. Today, the stock has fluctuated between ₹ 115.00 and ₹ 118.49. Over the past year, LYKA LABS LTD has achieved a return of 7.22 %. In the last month alone, the return has been 4.44 %. Read More...

LYKA LABS LTD fundamentals


  • Market cap (Cr)

    412.30

  • P/E Ratio (TTM)

    50.06

  • Beta

    1.31

  • Book Value / share

    37.80

  • Return on equity

    0.00%

  • EPS (TTM)

    2.31

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    1.31

info icon alternate text
  • Market cap (Cr)

    412.80

  • P/E Ratio (TTM)

    50.06

  • Beta

    1.27

  • Book Value / share

    37.80

  • Return on equity

    0.00%

  • EPS (TTM)

    2.31

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    1.31

info icon alternate text

LYKA LABS LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 30.52
Operating Expense 28.97
Net Profit 1.31
Net Profit Margin (%) 4.29
Earnings Per Share (EPS) 0.36
EBITDA 4.13
Effective Tax Rate (%) 42.73
Particulars DEC 2024 (Values in Cr)
Revenue 32.92
Operating Expense 30.21
Net Profit 2.70
Net Profit Margin (%) 8.20
Earnings Per Share (EPS) 0.75
EBITDA 5.96
Effective Tax Rate (%) 24.79
Particulars SEP 2024 (Values in Cr)
Revenue 41.16
Operating Expense 38.02
Net Profit 2.47
Net Profit Margin (%) 6.00
Earnings Per Share (EPS) 0.69
EBITDA 5.47
Effective Tax Rate (%) 24.46
Particulars JUN 2024 (Values in Cr)
Revenue 30.10
Operating Expense 28.38
Net Profit 1.75
Net Profit Margin (%) 5.81
Earnings Per Share (EPS) 0.49
EBITDA 4.68
Effective Tax Rate (%) 25.53
Particulars MAR 2024 (Values in Cr)
Revenue 26.98
Operating Expense 28.58
Net Profit -1.62
Net Profit Margin (%) -6.00
Earnings Per Share (EPS) 0.50
EBITDA 2.60
Effective Tax Rate (%) -33.88
Particulars MAR 2025 (Values in Cr)
Revenue 134.70
Operating Expense 125.56
Net Profit 8.23
Net Profit Margin (%) 6.10
Earnings Per Share (EPS) 2.28
EBITDA 20.22
Effective Tax Rate (%) 28.33
Particulars MAR 2024 (Values in Cr)
Revenue 106.40
Operating Expense 108.92
Net Profit -2.27
Net Profit Margin (%) -2.13
Earnings Per Share (EPS) -0.72
EBITDA 16.16
Effective Tax Rate (%) -144.08
Particulars MAR 2023 (Values in Cr)
Revenue 80.59
Operating Expense 90.08
Net Profit -13.29
Net Profit Margin (%) -16.49
Earnings Per Share (EPS) -4.65
EBITDA 11.87
Effective Tax Rate (%) -0.60
Particulars MAR 2022 (Values in Cr)
Revenue 164.35
Operating Expense 102.16
Net Profit 39.90
Net Profit Margin (%) 24.27
Earnings Per Share (EPS) 13.87
EBITDA 95.55
Effective Tax Rate (%) 33.76
Particulars MAR 2021 (Values in Cr)
Revenue 62.26
Operating Expense 81.44
Net Profit -14.46
Net Profit Margin (%) -23.22
Earnings Per Share (EPS) -5.08
EBITDA 15.20
Effective Tax Rate (%) 21.41
Particulars MAR 2024 (Values in Cr)
Book Value / Share 17.86
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.14
EBITDA Margin 15.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 9.12
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 3.36
EBITDA Margin 21.75
Particulars MAR 2022 (Values in Cr)
Book Value / Share 4.65
ROE % 77.59
ROCE % 40.57
Total Debt to Total Equity 0.00
EBITDA Margin 53.20
Particulars MAR 2021 (Values in Cr)
Book Value / Share -8.99
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 23.33
Particulars MAR 2020 (Values in Cr)
Book Value / Share -5.00
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 7.82
EBITDA Margin -0.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 27.28
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.73
EBITDA Margin 15.18
Particulars MAR 2023 (Values in Cr)
Book Value / Share 19.22
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.64
EBITDA Margin 23.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 15.49
ROE % 58.27
ROCE % 35.98
Total Debt to Total Equity 5.77
EBITDA Margin 58.14
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1.54
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 12.15
EBITDA Margin 24.41
Particulars MAR 2020 (Values in Cr)
Book Value / Share 6.55
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.91
EBITDA Margin -1.52
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.94
Total Assets 156.72
Total Liabilities 156.72
Total Equity 68.26
Share Outstanding 33090000
Price to Book Ratio 3.88
Return on Assets (%) -1.58
Return on Capital (%) -1.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 11.71
Total Assets 151.52
Total Liabilities 151.52
Total Equity 45.67
Share Outstanding 30690000
Price to Book Ratio 5.45
Return on Assets (%) -8.71
Return on Capital (%) -11.26
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.05
Total Assets 185.61
Total Liabilities 185.61
Total Equity 13.49
Share Outstanding 28690000
Price to Book Ratio 8.75
Return on Assets (%) 21.01
Return on Capital (%) 27.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 7.15
Total Assets 190.01
Total Liabilities 190.01
Total Equity -25.09
Share Outstanding 28690000
Price to Book Ratio 16.88
Return on Assets (%) -6.08
Return on Capital (%) -8.45
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 10.30
Total Assets 200.16
Total Liabilities 200.16
Total Equity -15.11
Share Outstanding 28690000
Price to Book Ratio 1.95
Return on Assets (%) -30.24
Return on Capital (%) -48.28
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.88
Total Assets 185.88
Total Liabilities 185.88
Total Equity 99.32
Share Outstanding 33090000
Price to Book Ratio 3.88
Return on Assets (%) -1.22
Return on Capital (%) -1.46
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.69
Total Assets 178.85
Total Liabilities 178.85
Total Equity 76.42
Share Outstanding 30690000
Price to Book Ratio 5.45
Return on Assets (%) -7.42
Return on Capital (%) -9.01
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.38
Total Assets 208.51
Total Liabilities 208.51
Total Equity 44.43
Share Outstanding 28690000
Price to Book Ratio 8.75
Return on Assets (%) 19.13
Return on Capital (%) 23.11
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6.52
Total Assets 213.37
Total Liabilities 213.37
Total Equity 4.40
Share Outstanding 28690000
Price to Book Ratio 16.88
Return on Assets (%) -6.77
Return on Capital (%) -8.73
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 8.40
Total Assets 221.26
Total Liabilities 221.26
Total Equity 18.77
Share Outstanding 28690000
Price to Book Ratio 1.95
Return on Assets (%) -25.03
Return on Capital (%) -35.72
Particulars MAR 2024 (Values in Cr)
Net Income -0.93
Cash from Operations 3.29
Cash from Investing -9.48
Cash from Financing 1.95
Net change in Cash -5.76
Free Cash Flow 12.52
Particulars MAR 2023 (Values in Cr)
Net Income -13.17
Cash from Operations 8.74
Cash from Investing 7.35
Cash from Financing -21.64
Net change in Cash -5.33
Free Cash Flow 16.93
Particulars MAR 2022 (Values in Cr)
Net Income 59.24
Cash from Operations 80.16
Cash from Investing -6.17
Cash from Financing -63.17
Net change in Cash 9.89
Free Cash Flow 87.67
Particulars MAR 2021 (Values in Cr)
Net Income -14.14
Cash from Operations 9.61
Cash from Investing -0.16
Cash from Financing -11.79
Net change in Cash -3.14
Free Cash Flow 10.88
Particulars MAR 2020 (Values in Cr)
Net Income -61.87
Cash from Operations 4.82
Cash from Investing -0.10
Cash from Financing 3.38
Net change in Cash 8.59
Free Cash Flow 5.92
Particulars MAR 2024 (Values in Cr)
Net Income -0.93
Cash from Operations 4.55
Cash from Investing -8.60
Cash from Financing 2.70
Net change in Cash -2.80
Free Cash Flow 13.79
Particulars MAR 2023 (Values in Cr)
Net Income -13.20
Cash from Operations 7.28
Cash from Investing 6.76
Cash from Financing -20.32
Net change in Cash -6.68
Free Cash Flow 16.11
Particulars MAR 2022 (Values in Cr)
Net Income 60.24
Cash from Operations 77.08
Cash from Investing -4.32
Cash from Financing -63.35
Net change in Cash 8.85
Free Cash Flow 83.00
Particulars MAR 2021 (Values in Cr)
Net Income -18.39
Cash from Operations 6.47
Cash from Investing 0.12
Cash from Financing -7.75
Net change in Cash -1.87
Free Cash Flow 7.73
Particulars MAR 2020 (Values in Cr)
Net Income -55.15
Cash from Operations -12.21
Cash from Investing 0.12
Cash from Financing 19.60
Net change in Cash 8.28
Free Cash Flow -11.64
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

LYKA LABS LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
115.53 -2.71 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 116.90
  • 26 Days 116.00
  • 10 Days 117.10
  • 50 Days 115.50
  • 12 Days 117.10
  • 100 Days 119.50
  • 20 Days 116.60
  • 200 Days 124.60
120.09 PIVOT

First Support

116.79

First Resistance

122.06

Second Support

114.82

Second Resistance

125.36

Third Support

111.52

Third Resistance

127.33

RSI

49.06

ADX

42.66

MACD

1.05

Williams % R

-90.32

Commodity Channel Index (CCI)

-85.85

Date

2025-06-13

Week

31738.00

Same Day

20796.00

Month

37917.00

1 Year

1.32

3 Year

0.91

Over 1 Month

4.44%

down

Over 1 Year

7.22%

down

Over 3 Months

16.30%

down

Over 3 Years

-2.82%

down

Over 6 Months

-28.55%

down

Over 5 Years

45.52%

down

LYKA LABS LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
40.94%
Promoter Holdings
58.16%
FII
0.23%
DII
0.66%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Ipca Laboratories Limited 1.4624923E7 (40.98%) Shareholding of Promoter and Promoter Group
Kunal Narendra Gandhi 3493629.0 (9.79%) Shareholding of Promoter and Promoter Group
Nehal Narendra Gandhi 1236371.0 (3.46%) Shareholding of Promoter and Promoter Group
Enai Trading And Investment Pvt. Ltd 1000000.0 (2.8%) Shareholding of Promoter and Promoter Group
Thermo Capital Private Limited 554237.0 (1.55%) Public Shareholding
Dalal & Broacha Stock Broking Pvt.ltd. 400000.0 (1.12%) Public Shareholding
Pranay Godha 300000.0 (0.84%) Shareholding of Promoter and Promoter Group
Alisha Kunal Gandhi 45000.0 (0.13%) Shareholding of Promoter and Promoter Group
Lyka Generics Limited 20000.0 (0.06%) Shareholding of Promoter and Promoter Group
Premchand Godha 10900.0 (0.03%) Shareholding of Promoter and Promoter Group
Usha Premchand Godha 10686.0 (0.03%) Shareholding of Promoter and Promoter Group
Neetu Godha 10000.0 (0.03%) Shareholding of Promoter and Promoter Group
Bhawna Godha 6000.0 (0.02%) Shareholding of Promoter and Promoter Group
Hiralaxmi Business Finance Pvt Ltd 708.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

LYKA LABS LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

LYKA LABS LTD Share Price

Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The Company is engaged in the business of pharmaceutical and related activities, including research.

The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking.

A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance.

During 1997-98, the company's administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system by SGS Yarsley International Certification Services Limited, UK.

The production carried out at Bombay has been shifted to Tarapur and Ankleshwar in the year 1999-2000, inorder to achieve economies of scale and better compliance. The company has assigned Trade Marks and transferred technical, marketing know-how and allied rights pertaining to some of its products.

The Company's factory at Tarapur, re-commissioned production in March, 2013. It launched Glutathione Injection, a 'First Time in India' formulation during 2012-13. It commissioned the production at Ankleshwar factory.

During Financial Year 2013-14, the Company had floated a Wholly Owned Subsidiary Company namely Lyka Healthcare Limited to focus, develop and expand Domestic Marketing of Ethical Products. Its another subsidiary, Lyka Exports Limited reorganized its activities and resultant, it sold the Animal Healthcare Business in 2014. The subsidiaries, Lyka Healthcare Limited and Lyka Exports Limited merged with the Company which became effective from April 01, 2016.

During the year 2021-22, IPCA together with persons acting in concert acquired 26.70% shares of the Company through Public Offer consisting a total shareholding of 27.76% of the Paid-up Equity Capital of the Company and resultant to acquisition in stake, became the Joint Promoters of Company.

The Company has acquired the animal healthcare business of the Agilis Healthcare Private Limited in 2023.

Parent organization Indian Private
NSE symbol LYKALABS
Founded 1976
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Lyka Labs Ltd?

Answer Field

The share price of Lyka Labs Ltd for NSE is ₹ 115.53 and for BSE is ₹ 115.65.

What is the Market Cap of Lyka Labs Ltd?

Answer Field

The market cap of Lyka Labs Ltd for NSE is ₹ 382.28 Cr. and for BSE is ₹ 382.68 Cr. as of now.

What is the 52 Week High and Low of Lyka Labs Ltd?

Answer Field

The 52 Week High and Low of Lyka Labs Ltd for NSE is ₹ 176.59 and ₹ 96.80 and for BSE is ₹ 175.95 and ₹ 90.20.

How to Buy Lyka Labs Ltd share?

Answer Field

You can trade in Lyka Labs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Lyka Labs Ltd?

Answer Field

The 1 year returns on the stock has been 7.22%.

What is the Current Share Price of Lyka Labs Ltd?

Answer Field

Lyka Labs Ltd share price is for NSE ₹ 115.53 & for BSE ₹ 115.65 as on Jun 13 2025 03:30 PM.

What is the Market Cap of Lyka Labs Ltd Share?

Answer Field

The market cap of Lyka Labs Ltd for NSE ₹ 382.28 & for BSE ₹ 382.68 as on Jun 13 2025 03:30 PM.

What is the P/E Ratio of Lyka Labs Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM the price-to-earnings (PE) ratio for Lyka Labs Ltd share is 50.06.

What is the PB ratio of Lyka Labs Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM, the price-to-book (PB) ratio for Lyka Labs Ltd share is 37.80.

How to Buy Lyka Labs Ltd Share?

Answer Field

You can trade in Lyka Labs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Lyka Labs Ltd Share on Bajaj Broking App?

Answer Field

To buy Lyka Labs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Lyka Labs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|